Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ).
Sihuan Pharmaceutical Holdings Group announced that their New Drug Application for a new indication of Bireociclib Tablets, in combination with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer, has been accepted by China’s National Medical Products Administration. This development highlights the company’s strong R&D capabilities and positions them to provide comprehensive treatment options for breast cancer patients, addressing a significant demand in the global market for CDK4/6 inhibitors, which is projected to grow substantially.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group, through its subsidiary Xuanzhu Biopharmaceutical, is an innovative pharmaceutical company based in China with a global outlook. The company focuses on major diseases such as oncology and digestion, and specializes in the research, development, production, and commercialization of class 1 drugs. Xuanzhu Biopharmaceutical employs a dual-platform approach with small molecule chemistry and large molecule biologics to drive innovation and development.
YTD Price Performance: 56.06%
Average Trading Volume: 75,703,865
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.61B
Find detailed analytics on 0460 stock on TipRanks’ Stock Analysis page.